The global immunomodulators market is expected to grow from USD 166.07 billion in 2019 to USD 247.92 billion by 2027, at a CAGR of 5.10% during the forecast period 2020-2027.
Immunomodulators are widely used in chronic illness and recommended for people with autoimmune diseases, as they help to restore immune system health in people who have been on lengthy courses of antibiotics or anti-viral therapies. There are ongoing trends of immunomodulation to combat a vast range of animal and human diseases including the incurable diseases like cancers, autoimmune diseases, viral diseases, and inflammatory conditions. Immunomodulators are most commonly used to treat patients with autoimmune disorders that is severe or moderate. The majority of new immunomodulators in development, which is likely to provide more growth opportunities in the market. Major players such as GSK and Pfizer are focusing on the development of new drugs.
Immunomodulators are natural or synthetic substances that modify or modulates the immune response. They help regulate or normalize the immune system by either stimulating or suppressing the immune system. Immunostimulants, such as interferons and vaccines, enhance the body’s resistance against infections. Immunomodulators generally classified into two categories: immunosuppressants and immunostimulants. Within each category, there are several types of medications, each with unique mechanisms of action, indications (both labeled and unlabeled), and with unique immune targets.
Global immunomodulators market is witnessing a considerable growth owing to increasing incidences of autoimmune diseases across the globe. Immunomodulator is an effective treatment for the people with autoimmune disease such as Crohn's disease and multiple sclerosis (MS). However, adverse effects of immunomodulators such as infection, both primary infection and reactivation of latent infections, anticipated to hinder the market, over the forecast period.
Major players in the global immunomodulators market are Hoffmann-La Roche Ltd., Amgen Inc., Abbott Laboratories, Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Merck & Co., Eli Lilly and Company, Pfizer Inc., Biogen Inc., Teva Pharmaceuticals, Pandion Therapeutics, Inc., and aTyr Pharma, Inc. among others. To enhance their market position in the global immunomodulators market, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership.
- In October 2019, Pandion Therapeutics, Inc. and Astellas Pharma Inc. announced the signing of a License and Collaboration Agreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of the pancreas.
- In January 2020, KYORIN Holdings, Inc. today announced that it’s wholly owned subsidiary KYORIN Pharmaceutical Co., Ltd has entered into a collaboration and license agreement with aTyr Pharma, Inc. for Japan with regard to ATYR1923, aTyr’s novel immunomodulator to develop and commercialize ATYR1923 for interstitial lung diseases in Japan.
Immunosuppressants segment led the immunomodulators market with the highest market share and valued at USD 88.76 billion in 2019
The type segment is divided into immunosuppressants and immunostimulants. The immunosuppressants segment further classified into calcineurin inhibitors, antimetabolites, glucocorticoids, and others. Immunostimulants further divided into vaccines, antibodies, others. Immunosuppressants segment led the immunomodulators market with the highest market share and valued at USD 88.76 billion in 2019. This is mainly attributed to presence of wide product range in this segment with the ability to treat the variety of autoimmune diseases.
The oral route of administration is estimated to grow at the highest CAGR of 6.9% over the forecast period
The route of administration segment includes oral, injectable, and intravenous. The oral route of administration is estimated to grow at the highest CAGR of 6.9% over the forecast period, as it is one of the most convenient and usually the safest and least expensive route of administration. After oral administration, these drugs quickly absorbed and approximately 30% circulate in the blood bound to plasma proteins.
Others (multiple sclerosis, Crohn's disease, rheumatoid arthritis, etc.) segment accounted for the major market share of 45.6% in 2019
The application segment includes respiratory, human immunodeficiency virus (HIV), oncology, and others. Other segment includes disease such as multiple sclerosis, Crohn's disease, rheumatoid arthritis, etc. Others segment accounted for the major market share of 45.6% in 2019. This is mainly due to wide used of immunomodulators for the treatment of these diseases. These drugs have been used for over two decades to treat relapsing these diseases. Imunomodulators help to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.
Regional Segment Analysis of the Immunomodulators Market
- North America (U.S. , Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of the Europe)
- Asia-Pacific (China, Japan India, Rest of APAC)
- South America (Brazil and Rest of South America)
- Middle East and Africa (UAE, South Africa, Rest of MEA)
The North America region emerged as the largest market for the immunomodulators market with a 38.7% share of the market revenue in 2019. This is because North America has the highest number of population suffering from the autoimmune diseases. In addition to this, presence of large number of companies in the region, positively impacting the growth of market. For instance, as per the study of National institute of Environmental Science, autoimmune diseases affect more than 24 million people in the United States. In addition to this, as per the National Multiple Sclerosis Society, Canada is the country, which has the highest prevalence of multiple sclerosis in the world. The Asia Pacific region is anticipated to hold the considerable market share in the global immunomodulators market, owing to rising awareness about various immune disorders, In addition to this, favorable government regulations and increasing healthcare expenditure in the countries such as India and China, further propelling the growth of market in the Asia Pacific region.
The global immunomodulators market is analysed on the basis of value (USD billion). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, and competitor position grid analysis.